Results 81 to 90 of about 8,768 (188)

The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension

, 2018
Hossein Karami,1 Hadi Darvishi-Khezri,2 Mehrnoush Kosaryan,1 Rosetta Akbarzadeh,2 Mojdeh Dabirian3 1Department of Pediatrics, Thalassemia Research Center (TRC), Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran; 2Student ...
Kosaryan M, Darvishi-Khezri H, Dabirian M, Akbarzadeh R, Karami H   +4 more
core  

Review of bosentan in the management of pulmonary arterial hypertension

Vascular Health and Risk Management, 2008
Eli Gabbay1, John Fraser2, Keith McNeil31Western Australian Lung Transplant Unit and Pulmonary Hypertension Service, Royal Perth Hospital, Western Australia, Australia; 2Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside ...
Eli Gabbay, John Fraser, Keith McNeil
doaj  

Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases

Reumatismo, 2011
Objective: Pulmonary arterial hypertension (PAH) is a rare but severe complication of connective tissue diseases (CTD), with a negative impact on patients survival.
M. Rizzo, S. Pontarollo, F. Tiso, R. Montisci, H. Marotta, F. Tona, S. Iliceto, F. Cozzi   +7 more
doaj   +1 more source

Bosentan for patients with chronic thromboembolic pulmonary hypertension

, 2009
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive disease leading to worsening functional status and reduced survival for those patients who cannot undergo pulmonary endarterectomy (PEA).
Potena A, Scarduelli C., Potena A., Harari S., Confalonieri M, Kodric M., Piattella M, Vassallo FG, Kodric M, Cassandro R, Piattella M., Harari S, Scarda A., Vassallo F. G., Cassandro R., Scarduelli C, Scarda A, Confalonieri M.   +17 more
core   +1 more source

Bosentan Alters Endo- and Exogenous Bile Salt Disposition in Sandwich-Cultured Human Hepatocytes

, 2021
Bosentan, a well-known cholestatic agent, was not identified as cholestatic at concentrations up to 200 µM based on the drug-induced cholestasis (DIC) index value, determined in a sandwich-cultured human hepatocyte (SCHH)-based DIC assay.
Vinken, Mathieu, Deferm, Neel,, Van Brantegem, Pieter,, Vinken, Mathieu,, Oorts, Marlies, Dreesen, Erwin, Oorts, Marlies,, Chatterjee, Sagnik,, Van Brantegem, Pieter, Chatterjee, Sagnik, Annaert, Pieter, Dreesen, Erwin,, Cooreman, Axelle,, Richert, Lysiane, Cooreman, Axelle, Annaert, Pieter,, Deferm, Neel, Richert, Lysiane,   +17 more
core   +1 more source

An Open-Label, Multicentre Pilot Study of Bosentan in Pulmonary Arterial Hypertension Related to Congenital Heart Disease

Canadian Respiratory Journal, 2006
BACKGROUND: Bosentan has been shown to be a safe and efficacious treatment for idiopathic pulmonary arterial hypertension (PAH) and PAH associated with connective tissue disease.
Reda Ibrahim, John T Granton, Sanjay Mehta   +2 more
doaj   +1 more source

Effect of bosentan on intimal hyperplasia of carotid artery anastomoses in rabbits

Türk Kardiyoloji Derneği Arşivi, 2014
Objectives: We investigated the effect of bosentan on intimal hyperplasia of carotid artery anastomoses in rabbits. Study design: Eighteen New Zealand male rabbits were randomized into two groups, as drug (Group B) and non-drug (Group A).
Artan Jahollari, Anar Emrahov, Murat Tavlaşoğlu, Mustafa Kürklüoğlu, Mehmet Ali Şahin, Adem Güler, Ertuğrul Özal, Mehmet Arslan   +7 more
doaj   +1 more source

Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension

, 2011
In this article, we review randomized controlled trials, open-label trials and pharmacoeconomic models of bosentan for the management of patients with pulmonary arterial hypertension.
Keogh, A (15533573), Gabbay, E (15523910), Dalton, B (15533570), Strange, G (15519611)   +3 more
core  

BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis

, 2011
RATIONALE: A previous trial of bosentan in idiopathic pulmonary fibrosis (IPF) showed a trend to delayed IPF worsening or death. Also, improvements in some measures of dyspnea and health-related quality of life were observed.
Leconte, Isabelle
core   +1 more source

Additive Protective Effects of Sacubitril/Valsartan and Bosentan on Vascular Remodeling in Experimental Pulmonary Hypertension

, 2020
International audienceAims: Although right ventricular (RV) function is an important determinant of morbidity and mortality in patients with pulmonary arterial hypertension (PAH), there is no treatment targeting directly the RV. We therefore evaluate the
Huertas, Alice, Chaumais, Marie-Camille, Marie-Camille Chaumais, Gaignard, Pauline, Humbert, Marc, Guignabert, Christophe, Cumont, Amélie, Pauline Gaignard, Mohamed Reda Amar Djessa, Raphaël Thuillet, Alice Huertas, Thuillet, Raphaël, Ly Tu, Hébert, Guillaume, Savale, Laurent, Marc Humbert, Djessas, Mohamed Reda Amar, Guillaume Hebert, Christophe Guignabert, Amélie Cumont, Tu, Ly, Laurent Savale   +21 more
core   +1 more source